Immunotherapies targeting the T-cell immune inhibitory receptors, cytotoxic T-lymphocyte-associated antigen-4 (CTLA4) and programmed cell death-1 (PD1), have transformed clinical management of patients with a range of advanced cancers. Here, PDCD1 is linked to cancer.